CC
BIIB icon

Curian Capital’s Biogen BIIB Stock Holding History

Curian Capital’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-7,921
Closed -$2.43M – 40
2015
Q4 		$2.43M Sell
7,921
-14,470
-65% -$4.16M 0.18% 127
2015
Q3 		$6.53M Sell
22,391
-540
-2% -$178K 0.17% 147
2015
Q2 		$9.26M Sell
22,931
-3,379
-13% -$1.36M 0.16% 162
2015
Q1 		$11.1M Sell
26,310
-5,658
-18% -$2.23M 0.19% 136
2014
Q4 		$10.9M Buy
31,968
+4,458
+16% +$1.44M 0.18% 134
2014
Q3 		$9.1M Buy
27,510
+946
+4% +$312K 0.16% 159
2014
Q2 		$8.38M Buy
26,564
+4,382
+20% +$1.32M 0.15% 172
2014
Q1 		$6.79M Sell
22,182
-12,885
-37% -$4.09M 0.12% 195
2013
Q4 		$9.8M Buy
35,067
+3,830
+12% +$991K 0.17% 146
2013
Q3 		$7.52M Sell
31,237
-353
-1% -$79K 0.13% 163
2013
Q2 		$6.8M Buy
+31,590
New +$6.75M 0.12% 158

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Curian Capital's BIIB Position: Q1 2016 in Review

Curian Capital sold out of Biogen (BIIB) in Q1 2016, closing a stake of 7,921 shares — an estimated $2.43M sold.

Curian Capital first reported a position in BIIB in Q2 2013 and held it in 11 quarters. The position peaked at $11.1M in Q1 2015. 947 funds tracked by Wall St. Rank hold BIIB as of Q1 2016.

  • Curian Capital reported no remaining Biogen position as of Q1 2016 after selling out during the quarter.
  • Curian Capital sold 7,921 Biogen shares in Q1 2016, an estimated $2.43M.
  • Curian Capital first reported a position in Biogen in Q2 2013 and held it in 11 quarters.
  • Curian Capital's Biogen position peaked at $11.1M in Q1 2015.
  • 947 funds tracked by Wall St. Rank held Biogen as of Q1 2016.

Based on Curian Capital's 13F filing for Q1 2016.